RxDoctor Payments DataLook up a doctor →

Paul Smith, MD

Family Medicine · Reno, NVNPI 1912093964

Payments from drug & device makers

$10,008in general payments, 2019–2025

Across 573 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$981
  • Amarin Pharma, Inc.$939
  • AstraZeneca$849
  • Johnson & Johnson$848
  • Novartis$426
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$9,972100%
  • Education$350%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,008 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$103,844
Medicare patients
254
Services billed
1,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$80,704
Repatha SureclickEvolocumab66$70,663
EliquisApixaban38$52,553
VascepaIcosapent Ethyl68$50,145
XareltoRivaroxaban40$43,651
RybelsusSemaglutide19$31,945
MyrbetriqMirabegron24$30,688
FarxigaDapagliflozin Propanediol20$28,324
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$26,649
JardianceEmpagliflozin15$25,913
Praluent PenAlirocumab26$19,024
Spiriva RespimatTiotropium Bromide20$14,012
ArexvyRsvpref3 Antigen/As01e/Pf39$12,227
LinzessLinaclotide14$9,444
BelsomraSuvorexant13$8,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$376$112,64965 claims
PfizerEliquis, Premarin, Paxlovid$334$62,00172 claims
Johnson & JohnsonXarelto$848$43,65140 claims
GSKTrelegy Ellipta, Arexvy, Incruse Ellipta$415$43,03685 claims
Boehringer IngelheimJardiance, Spiriva Respimat$331$39,92535 claims
Astellas Pharma US IncMyrbetriq$321$30,68824 claims
AstraZenecaFarxiga$849$28,32420 claims
MerckBelsomra, Dulera$262$14,87729 claims
AbbVieLinzess, Synthroid$1,270$13,07368 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.

Other family medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →